Contact

All Stories

  1. Influence of age on the pharmacokinetics, pharmacodynamics, efficacy, and safety of rivaroxaban

    Article • Current Medical Research and Opinion, August 2018, Taylor & Francis

    Mr Kenneth Todd Moore

  2. Clarification of the use of rivaroxaban in renal patients

    Article • British Journal of Haematology, July 2018, Wiley

    Mr Kenneth Todd Moore

  3. Clarification-safety and efficacy of apixaban versus warfarin in patients with end-stage renal disease: Meta-analysis

    Article • Pacing and Clinical Electrophysiology, June 2018, Wiley

    Mr Kenneth Todd Moore

  4. Rivaroxaban reversal with prothrombin complex concentrate or tranexamic acid in healthy volunteers

    Article • Journal of Thrombosis and Haemostasis, December 2017, Wiley

    Mr Kenneth Todd Moore

  5. A Cross-Study Analysis Evaluating the Effects of Food on the Pharmacokinetics of Rivaroxaban in Clinical Studies

    Article • The Journal of Clinical Pharmacology, July 2017, Wiley

    Mr Kenneth Todd Moore

  6. Influences of Obesity and Bariatric Surgery on the Clinical and Pharmacologic Profile of Rivaroxaban

    Article • The American Journal of Medicine, June 2017, Elsevier

    Mr Kenneth Todd Moore

  7. The Clinical Pharmacology of Rivaroxaban, a Factor Xa inhibitor, in Chronic Hemodialysis

    Article • American Journal of Nephrology, April 2016, Karger Publishers

    Mr Kenneth Todd Moore

  8. Rivaroxaban in Chronic Hemodialysis Patients: Clarification of an Editorial Error

    Article • American Journal of Nephrology, January 2016, Karger Publishers

    Mr Kenneth Todd Moore

  9. Switching from rivaroxaban to warfarin: an open label pharmacodynamic study in healthy subjects

    Article • British Journal of Clinical Pharmacology, May 2015, Wiley

    Mr Kenneth Todd Moore

  10. Randomized, blinded, placebo- and positive-controlled crossover study to determine the effect of multiple doses of apixaban on the QTc interval

    Article • The Journal of Clinical Pharmacology, January 2015, Wiley

    Mr Kenneth Todd Moore

  11. Comparison of three‐factor and four‐factor prothrombin complex concentrates regarding reversal of the anticoagulant effects of rivaroxaban in healthy volunteers

    Article • Journal of Thrombosis and Haemostasis, September 2014, Elsevier

    Mr Kenneth Todd Moore

  12. An open‐label study to estimate the effect of steady‐state erythromycin on the pharmacokinetics, pharmacodynamics, and safety of a single dose of rivaroxaban in subjects with renal impairment and normal renal function

    Article • The Journal of Clinical Pharmacology, July 2014, Wiley

    Mr Kenneth Todd Moore

  13. Rivaroxaban crushed tablet suspension characteristics and relative bioavailability in healthy adults when administered orally or via nasogastric tube

    Article • Clinical Pharmacology in Drug Development, May 2014, Wiley

    Mr Kenneth Todd Moore

  14. Population pharmacokinetics and pharmacodynamics of rivaroxaban in patients with non‐valvular atrial fibrillation: Results from ROCKET AF

    Article • The Journal of Clinical Pharmacology, March 2014, Wiley

    Mr Kenneth Todd Moore

  15. Rivaroxaban: a novel oral anticoagulant for the prevention and treatment of several thrombosis-mediated conditions

    Article • Annals of the New York Academy of Sciences, May 2013, Wiley

    Mr Kenneth Todd Moore

  16. Randomized 5-Treatment Crossover Study to Assess the Effects of External Heat on Serum Fentanyl Concentrations During Treatment With Transdermal Fentanyl Systems

    Article • The Journal of Clinical Pharmacology, August 2012, Wiley

    Mr Kenneth Todd Moore

  17. Population pharmacokinetics and pharmacodynamics of rivaroxaban in patients with acute coronary syndromes

    Article • British Journal of Clinical Pharmacology, June 2012, Wiley

    Mr Kenneth Todd Moore

  18. Effect of Mild and Moderate Hepatic Impairment on the Pharmacokinetics and Safety of Carisbamate

    Article • The Journal of Clinical Pharmacology, May 2012, Wiley

    Mr Kenneth Todd Moore

  19. Effect of Multiple Doses of Omeprazole on the Pharmacokinetics, Pharmacodynamics, and Safety of a Single Dose of Rivaroxaban

    Article • Journal of Cardiovascular Pharmacology, December 2011, Wolters Kluwer Health

    Mr Kenneth Todd Moore

  20. A Randomized Study of the Effects of Food on the Pharmacokinetics of Once-Daily Extended-Release Hydromorphone in Healthy Volunteers

    Article • The Journal of Clinical Pharmacology, November 2011, Wiley

    Mr Kenneth Todd Moore